Victory Capital Management
TRVI icon

Victory Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Victory Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
+10,705
New +$156K ﹤0.01% 2269
2020
Q2 		– Sell
-803
Closed -$3K – 3229
2020
Q1 		$3K Buy
+803
New +$3.65K ﹤0.01% 3424
2019
Q4 		– Sell
-986
Closed -$4K – 3234
2019
Q3 		$4K Buy
+986
New +$5.36K ﹤0.01% 3520

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Victory Capital Management's TRVI Position: Q2 2026 in Review

Victory Capital Management opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 10,705 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #2269 among its holdings. This is a return to the name: Victory Capital Management previously reported a position in TRVI as recently as Q1 2020.

Victory Capital Management first reported a position in TRVI in Q3 2019 and has held it in 3 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Victory Capital Management held 10,705 shares of Trevi Therapeutics worth $200K as of Q2 2026.
  • Trevi Therapeutics was a new Victory Capital Management position in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2269 holding.
  • Victory Capital Management first reported a position in Trevi Therapeutics in Q3 2019 and has held it in 3 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.